Abstract
The activity of telavancin and comparators was assessed against a contemporary (2007 and 2008) global collection of 10,000 isolates of Staphylococcus aureus. Telavancin was very active against methicillin-susceptible and -resistant S. aureus (MSSA and MRSA, respectively; MIC(50/90) for both, 0.12/0.25 microg/ml; 100.0% susceptible). This agent was 2-, 4-, and 8-fold more potent than daptomycin (MIC(90), 0.5 microg/ml), vancomycin or quinupristin-dalfopristin (MIC(90), 1 microg/ml), and linezolid (MIC(90), 2 microg/ml) against MRSA, respectively. These data show a potent activity of telavancin tested against a current global collection of S. aureus.
MeSH terms
-
Acetamides / pharmacology
-
Aminoglycosides / pharmacology*
-
Anti-Bacterial Agents / pharmacology*
-
Daptomycin / pharmacology
-
Drug Resistance, Bacterial
-
Humans
-
In Vitro Techniques
-
Linezolid
-
Lipoglycopeptides
-
Methicillin Resistance
-
Methicillin-Resistant Staphylococcus aureus / drug effects
-
Methicillin-Resistant Staphylococcus aureus / isolation & purification
-
Microbial Sensitivity Tests
-
Oxazolidinones / pharmacology
-
Staphylococcal Infections / drug therapy*
-
Staphylococcal Infections / microbiology*
-
Staphylococcus aureus / drug effects*
-
Staphylococcus aureus / isolation & purification
-
Vancomycin / pharmacology
-
Virginiamycin / pharmacology
Substances
-
Acetamides
-
Aminoglycosides
-
Anti-Bacterial Agents
-
Lipoglycopeptides
-
Oxazolidinones
-
Virginiamycin
-
quinupristin-dalfopristin
-
Vancomycin
-
Linezolid
-
Daptomycin
-
telavancin